Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.59 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113212 | 0.85 | CYP4F2 (0.76) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL9650739 | 0.84 | CYP4F2 (0.63) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL3133941 | 0.82 | CYP4F2 (0.61) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL479979 | 0.82 | CYP4F2 (0.61) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL1198228 | 0.82 | LOXL2 (0.63) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL4123759 | 0.81 | CYP4A11 (0.47) | CYP4F2CYP4A11MAPTLMNAALDH1A1 | |
| SCHEMBL7326535 | 0.81 | CYP4F2 (0.56) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL23582497 | 0.81 | CYP4F2 (0.59) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL4019274 | 0.80 | CYP4F2 (0.63) | CYP4F2CYP4A11SMN1; SMN2MAPTLMNA | |
| SCHEMBL191324 | 0.80 | CYP4F2 (0.63) | CYP4F2CYP4A11MAPTALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4211117-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | Loxo Oncology, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-116323553-A | Processes and intermediates for preparing (S) -5-amino-3- (4- ((5-fluoro-2-methoxybenzamido) methyl) phenyl) -1- (1, 1-trifluoropropan-2-yl) -1H-pyrazole-4-carboxamide | 罗索肿瘤学公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2022056100-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-101952263-A | Romp-polymerizable electron transport materials based on a bis-oxadiazole moiety | GEORGIA TECH RES INST | 2011-01-19 | — | — | CN | disclosed |
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2234991-A1 | ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY | Georgia Tech Research Corporation (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080797-A1 | ROMP-POLYMERIZABLE ELECTRON TRANSPORT MATERIALS BASED ON A BIS-OXADIAZOLE MOIETY | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-07-02 | — | — | WO | disclosed |
| US-4501912-A | AMINO-2-HYDROXYROPYLBENZOATE COMPOUND OR SALT WITH LONG DURATION IN OCULAR FLUID; RAPID METABOLISM | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-02-26 | — | — | US | disclosed |
| US-4402974-A | WITH CARBOXY, OXY, CARBO-AMINE | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1983-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009584-A1 | Romp-Polymerizable Electron Transport Materials Based On A Bis-Oxadiazole Moiety | SLCO1B3, SLCO4C1, SLCO2B1 | CYP4F2 738/4885CYP4A11 1604/4885SMN1; SMN2 2957/4885 |
| US-20230322682-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | CYP4B1, PFAS, CYP2E1 | CYP4F2 86/4885CYP4A11 309/4885SMN1; SMN2 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.